Special Issue

Novel Therapeutic Strategies for Glioblastoma

Message from the Guest Editors

Adult glioblastoma is the most common and most aggressive type of primary brain cancer. It is a highly heterogenic cancer whose malignant cells are invasive and intrinsically resistant to any applied therapy. Despite numerous clinical studies that have been conducted in the last two decades, glioblastoma remains unresponsive to diverse available therapies (targeted molecular therapeutics, cellular and immune therapies, as well as alternating electrical fields). The standard procedure, dating from 2005, is surgical resection followed by radiotherapy with concomitant temozolomide chemotherapy; it has failed to prolong glioblastoma patient survival. Therefore, new therapeutic strategies that can overcome glioblastoma resistance and recurrence and improve patient survival are necessary. This Special Issue will assemble preclinical and clinical studies of novel therapeutic strategies for glioblastoma. In addition, reviews referring to glioblastoma research and therapy will be appreciated.

- glioblastoma
- novel therapeutic strategies
- preclinical models
- clinical studies
- resistance to therapy
- gene therapy
- stem cell therapy
- immunotherapy
- natural compounds

Guest Editors

Dr. Milica Pešić

Dr. Ana Podolski-Renić

Dr. Jelena Dinić

Deadline for manuscript submissions

closed (31 December 2024)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/121970

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

